Company news

Amgen Inc. news in 2025

Amgen Inc.'s news releases, calls and decks from 2025, newest first.

View company

Amgen takes action with the U.S. government to lower the cost of medicines for American patients

December 18, 2025

FDA approves UPLIZNA® for adults with generalized Myasthenia Gravis

December 10, 2025

Amgen announces 2026 first quarter dividend

December 8, 2025

Inductive Bio Announces an Up To $21M Award to Develop AI Drug Toxicity Models that Improve Drug Safety Assessment with Leading Academic and Biopharmaceutical Organizations

December 8, 2025

The Los Angeles Sports & Entertainment Commission (LASEC) Names Amgen as Official Biotech Partner and Los Angeles World Cup 2026 Host City Supporter Ahead of FIFA World Cup 2026™

December 5, 2025

Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health

December 2, 2025

Amgen to present at citi's 2025 global healthcare conference

November 23, 2025

Amgen to present at the 8th annual evercore isi healthconx conference

November 23, 2025

FDA grants full approval to Amgen's IMDELLTRA® in extensive stage small cell lung cancer

November 18, 2025

Amgen's Repatha® cuts risk of first major adverse cardiovascular events by 25% in landmark Phase 3 VESALIUS-CV trial

November 7, 2025

Quantinuum Announces Commercial Launch of New Helios Quantum Computer that Offers Unprecedented Accuracy to Enable Generative Quantum AI (GenQAI)

November 6, 2025

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

November 5, 2025

Amgen reports third quarter 2025 financial results

November 3, 2025

Amgen's landmark Phase 3 Repatha data to be presented as late breaker at the american heart association scientific sessions 2025

October 30, 2025

Amgen announces 2025 fourth quarter dividend

October 30, 2025

Amgen announces webcast of 2025 third quarter financial results

October 28, 2025

Agilent Names Adam S. Elinoff as Chief Financial Officer

October 27, 2025

FDA approves TEZSPIRE® for chronic rhinosinusitis with nasal polyps

October 16, 2025

Correction: Amgen

October 5, 2025

Landmark Phase 3 trial (VESALIUS-CV) meets primary endpoints in a cardiovascular primary prevention study of 12,000 patients

October 1, 2025

Amgen announces $650M expansion of U.S. manufacturing, creating hundreds of new jobs

September 25, 2025

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

September 8, 2025

Amgen and Kyowa Kirin announce top-line results from rocatinlimab Phase 3 ASCEND long-term extension study in adults with moderate to severe atopic dermatitis

September 7, 2025

Amgen to present at the morgan stanley 23rd annual global healthcare conference

September 3, 2025

Amgen investing more than half a billion dollars in new, state-of-the-art center for science and innovation at U.S. global headquarters

September 1, 2025

Amgen to present at the 2025 wells fargo healthcare conference

August 28, 2025

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation

August 28, 2025

Repatha® now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C

August 24, 2025

Singzyme wins 2025 Amgen x NSG golden ticket for breakthrough bioconjugation platform

August 21, 2025

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

August 6, 2025

Amgen reports second quarter 2025 financial results

August 4, 2025

Amgen announces 2025 third quarter dividend

July 31, 2025

Amgen announces webcast of 2025 second quarter financial results

July 30, 2025

PharmaVentures Appoints Samara Ferguson as Vice President to Lead Pricing and Market Access Team

July 3, 2025

mAbxience Announces European Commission Approval of Denosumab Biosimilars

July 2, 2025

Amgen announces positive topline Phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (FGFR2b) positive first-line gastric cancer

June 29, 2025

Results from Amgen's Phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions

June 22, 2025

Amgen's Phase 2 MariTide data to be presented at the American Diabetes Association 85th Scientific Sessions

June 17, 2025

Amgen and football legend Barry Sanders highlight dangers of bad Cholesterol in new documentary

June 12, 2025

Amgen to present at goldman sachs 46th annual global healthcare conference

June 4, 2025

IMDELLTRA® significantly reduced risk of death by 40% in small cell lung cancer patients

June 1, 2025

Amgen to present at jefferies global healthcare conference

May 29, 2025

Amgen to present at the 2025 rbc capital markets global healthcare conference

May 15, 2025

Amgen to present at the bank of america merrill lynch global healthcare conference

May 8, 2025

Amgen reports first quarter 2025 financial results

April 30, 2025

Amgen announces webcast of 2025 first quarter financial results

April 27, 2025

Amgen announces $900 million manufacturing expansion, creation of 350 new jobs in Ohio

April 24, 2025

IMDELLTRA® demonstrated superior overall survival in small cell lung cancer

April 10, 2025

UPLIZNA® (inebilizumab-cdon) is now the first and only FDA-approved treatment for IGG4-related disease

April 2, 2025

UPLIZNA® (inebilizumab-cdon) significantly improves generalized myasthenia gravis symptoms in acetylcholine receptor autoantibody-positive patients over 52 weeks

March 12, 2025

Older news releases →

Calls in 2025

Decks in 2025